Key Drivers
- Liquidity comfortable
- Negative profitability
- Rising leverage
AIAI Summary
Evotec's shift to an asset‑light, milestone‑driven model transforms it into a binary execution bet—large upside if JEB/biologics milestones convert but acute downside if cost‑outs and milestone timing fail to stabilize free cash flow and leverage. Actionable: monitor near‑term milestone conversion dates, delivery of the remaining €50m cost‑outs, and cash‑runway/capital actions before increasing exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity comfortable
- •Negative profitability
- •Rising leverage
Evo shows adequate short-term liquidity and tangible assets but is undermined by collapsing gross margins, persistent operating losses, negative free cash flow, shrinking cash and rising leverage.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Lower highs/lows
- •Elevated volatility
EVO is in a clear downtrend—price trades well below the last-month SMA with lower highs/lows and may continue toward or below $2.31 unless it reclaims $2.92 and clears $3.40–$3.53 to reverse.
Rough one-third drop from $3.53 to $2.31 indicating elevated downside volatility
Sentiment & News
Key News Insights:
- •Strategic transformation
- •Clinical validation
- •Legal scrutiny
EVO's Horizon strategic push and a $10M partnered milestone underline operational and clinical momentum while a shareholder investigation introduces legal risk.
Clinical and partnership progress could drive upside from program de‑risking, but the shareholder investigation raises near‑term volatility and downside risk for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings